DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, presented results from a new clinical study of 940 members at the 20th Annual Diabetes Technology Society Meeting (“DTS”). According to the update, the results showed a marked reduction in the percentage of high blood glucose readings and in the average blood glucose readings in adults over the age of 65 years using Dario’s digital therapeutics platform (“Dario DTx”). “We believe that Dario’s DTx platform plays a role in driving behavioral modification and enhances adherence to diabetes and other chronic condition management in older adults,” said Yifat Hershcovitz, Ph.D., scientific and clinical director at DarioHealth. “The results show that the platform can significantly reduce the percentage of high blood glucose ratios and may facilitate significant improvement in clinical outcomes, leading to better health outcomes for older individuals with diabetes.”
To view the full press release, visit https://ibn.fm/cS0uf
About DarioHealth Corp.
DarioHealth is a leading, global digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its consumer-centric MyDario(TM) mobile app is loved by tens of thousands of members worldwide. DarioHealth is rapidly moving into new geographic markets to meet the needs of additional chronic conditions, using a performance-based approach to improve members’ management of chronic disease. To learn more about the company and its digital health solutions, visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork